Pharmacomechanical Thrombolysis No Benefit in DVT

Share this content:
Pharmacomechanical Thrombolysis No Benefit in DVT
Pharmacomechanical Thrombolysis No Benefit in DVT

THURSDAY, Dec. 7, 2017 (HealthDay News) -- The addition of pharmacomechanical thrombolysis does not reduce the risk of post-thrombotic syndrome among patients with acute proximal deep vein thrombosis, according to a study published in the Dec. 7 issue of the New England Journal of Medicine.

Suresh Vedantham, M.D., from the Washington University School of Medicine in St. Louis, and colleagues randomized 692 patients with acute proximal deep-vein thrombosis to receive anticoagulation alone (control group) or anticoagulation plus pharmacomechanical thrombolysis.

The researchers found observed no significant between-group difference in the percentage of patients with post-thrombotic syndrome between six and 24 months (47 percent in the pharmacomechanical-thrombosis group and 48 percent in the control group; risk ratio, 0.96; 95 percent confidence interval, 0.82 to 1.11; P = 0.56). More bleeding events within 10 days occurred in the pharmacomechanical thrombolysis group (1.7 versus 0.3 percent of patients; P = 0.049); over the 24-month period, there was no significant difference in recurrent venous thromboembolism (12 versus 8 percent; P = 0.09). Moderate-to-severe post-thrombotic syndrome occurred in 18 and 24 percent of patients in the pharmacomechanical thrombolysis and control groups, respectively (risk ratio, 0.73; 95 percent confidence interval, 0.54 to 0.98; P = 0.04).

"Among patients with acute proximal deep-vein thrombosis, the addition of pharmacomechanical catheter-directed thrombolysis to anticoagulation did not result in a lower risk of the post-thrombotic syndrome but did result in a higher risk of major bleeding," the authors write.

Several authors disclosed ties to pharmaceutical companies, some of which provided funding for the study; BSN Medical donated compression stockings.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ground Beef Recalled After E. Coli Outbreak

Ground Beef Recalled After <i>E. Coli</i> Outbreak

Beef was produced and packaged at Cargill Meat Solutions in Fort Morgan, Colo.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

Alzheimer's disease and related dementias burden is expected to increase to 3.3 percent in 2060

Long-Term Outcomes of Breast Implants Explored

Long-Term Outcomes of Breast Implants Explored

Higher rates of Sjogren syndrome, scleroderma, RA, stillbirth, melanoma for silicone implants

is free, fast, and customized just for you!




Already a member?

Sign In Now »